Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin‐pump‐treated patients with type 1 diabetes: The Lira Pump trial—a randomized, double‐blinded, placebo‐controlled trial
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes"
DOI: 10.1111/dom.13911
Abstract: To investigate the efficacy of adding the glucagon‐like peptide‐1 receptor agonist liraglutide to continuous subcutaneous insulin infusion (CSII) in overweight or obese persons with type 1 diabetes and non‐optimal glycaemic control. read more here.
Keywords: reduces hyperglycaemia; insulin; trial; liraglutide reduces ... See more keywords